Tamsolin-S Tablets 0.4Mg+6 Mg (1 Strip = 10 Tablets)

Requires Prescription (YES/NO)

Yes

Generics

Tamsulosin HCl + Solifenacin succinate

Used For

Benign Prostatic Hyperplasia

How it works

Tamsulosin HCl: Tamsulosin HCl is an a1-adrenoceptor (AR) antagonist. It binds selectively and competitively to postsynaptic a1-ARs, in particular to subtypes a1a and a1d and is a potent antagonist in lower urinary tract tissues. Solifenacin succinate: Solifenacin succinate is a competitive and selective antagonist of muscarinic receptors and has no relevant affinity for various other receptors, enzymes and ion channels tested. Solifenacin succinate has the highest affinity for muscarinic M3-receptors, followed by muscarinic M1- and M2- receptors.

Dosage

Tamsulosin HCl + Solifenacin succinate

Side Effects

Tamsulosin HCl : Common: Dizziness, ejaculation disorder including retrograde ejaculation and ejaculation failure. Uncommon: Headache, orthostatic hypotension, rhinitis, constipation, nausea, diarrhea, vomiting, pruritus, rash, urticaria and asthenia. Rare: Syncope and angioedema. Solifenacin succinate : Very common: Dry mouth. Common: Constipation, nausea, dyspepsia, abdominal pain and blurred vision. Uncommon: Gastro esophageal reflux diseases, dry throat, urinary tract infection, cystitis, somnolence, dysgeusia, dry eyes, fatigue, peripheral edema, nasal dryness, dry skin and difficulty in micturation. Rare: Colonic obstruction, fecal impaction and urinary retention, dizziness, headache, vomiting, pruritus and rash.

Drug Interactions

Ketoconazole , verapamil , cimetidine , paroxetine , metoclopramide , cisapride , a1-adrenoceptor antagonists , CYP3A4 inducers (e.g., rifampicin) .

Indication

Tamsulosin HCl + Solifenacin succinate is indicated for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy.

When not to Use

Tamsulosin HCl + Solifenacin succinate is contraindicated in: - Patients with hypersensitivity to the active substance(s) or to any of the excipient of the product. - Patients undergoing hemodialysis. - Patients with severe hepatic impairment. - Patients with severe renal impairment who are also treated with a strong cytochrome P450 (CYP) 3A4 inhibitor, e.g., ketoconazole. - Patients with moderate hepatic impairment who are also treated with a strong CYP3A4 inhibitor, e.g., ketoconazole. - Patients with severe gastrointestinal conditions (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma and patients at risk for these conditions. - Patients with a history of orthostatic hypotension.

Precaution

The patient should be examined in order to exclude the presence of other conditions, which can cause similar symptoms to benign prostatic hyperplasia.

Warning 1

Other causes of frequent urination (heart failure or renal disease) should be assessed before treatment is initiated. If a urinary tract infection is present, appropriate antibacterial therapy should be started.

Warning 2

QT prolongation and Torsade de Pointes have been observed in patients with risk factors, such as pre-existing long QT syndrome and hypokalemia, who are treated with solifenacin succinate.

Warning 3

Angioedema with airway obstruction has been reported in some patients on tamsulosin HCl + solifenacin succinate. If angioedema occurs, treatment should be discontinued and not restarted. Appropriate therapy and/or measures should be taken .

Pregnancy category

Always consult your physician before using any medicine.

Storage (YES/NO)

Store this medicine at room temperature, away from direct light and heat.